Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

Conditions: WHO Grade III Gliomas; WHO Grade IV Gliomas Interventions: Biological: personalized dendritic cell injection ZSNeo-DC1.1 Sponsors: Beijing Tiantan Hospital; ZhongSheng BioTech Inc. Recruiting

https://clinicaltrials.gov/study/NCT06253234

Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials